Description: Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, which is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria in patients 2 years of age and older. Its products portfolio also include Cuvposa, which is indicated for sialorrhea in patients aged 3-18 years with neurologic conditions, such as cerebral; Gliolan, an orally administered drug used for the visualization of various brain tumors; and Treosulfan, a conditioning agent used prior to stem cell transplantation. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Verdun, Canada.
Home Page: www.medexus.com
35 Nixon Road
Bolton,
ON
L7E 1K1
Canada
Phone:
877 633 3987
Officers
| Name | Title |
|---|---|
| Mr. Kenneth d'Entremont | CEO & Director |
| Mr. Marcel Konrad | Chief Financial Officer |
| Mr. Michael David Adelman | Gen. Mang., U.S. Operations |
| Ms. Tina Byers CFA | Exec. of Investor Relations |
| Mr. Ian C. Wildgoose Brown | Gen. Counsel & Corp. Sec. |
| Mr. Bill Poncy | Sr. VP of Commercial Operations - United States |
| Mr. Brian Peters | VP of Sales & Marketing - United States |
Exchange: OTCQX
Country: US
Currency: US Dollar ($)
| Forward PE: | 133.3333 |
|---|---|
| Trailing PE: | 11.4615 |
| Price-to-Book MRQ: | 1.747 |
| Price-to-Sales TTM: | 0.3067 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 100 |